Experience with selegiline and levodopa in advanced Parkinson's disease
Identifieur interne : 000236 ( Main/Curation ); précédent : 000235; suivant : 000237Experience with selegiline and levodopa in advanced Parkinson's disease
Auteurs : A. Lieberman [États-Unis] ; E. Fazzini [États-Unis]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1991-10.
English descriptors
- KwdEn :
Abstract
We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.
Url:
DOI: 10.1111/j.1600-0404.1991.tb05022.x
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000283
Links to Exploration step
ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title><author><name sortKey="Lieberman, A" sort="Lieberman, A" uniqKey="Lieberman A" first="A." last="Lieberman">A. Lieberman</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona</wicri:regionArea></affiliation></author><author><name sortKey="Fazzini, E" sort="Fazzini, E" uniqKey="Fazzini E" first="E." last="Fazzini">E. Fazzini</name><affiliation wicri:level="1"><mods:affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Neurology New York University Medical Center New York, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1600-0404.1991.tb05022.x</idno><idno type="url">https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000283</idno><idno type="wicri:Area/Main/Curation">000236</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title><author><name sortKey="Lieberman, A" sort="Lieberman, A" uniqKey="Lieberman A" first="A." last="Lieberman">A. Lieberman</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona</wicri:regionArea></affiliation></author><author><name sortKey="Fazzini, E" sort="Fazzini, E" uniqKey="Fazzini E" first="E." last="Fazzini">E. Fazzini</name><affiliation wicri:level="1"><mods:affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Neurology New York University Medical Center New York, New York</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10">1991-10</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="69">69</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">6FCE6AA3CF3BCDB32A770203C4C85803B8469370</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05022.x</idno><idno type="ArticleID">ANE66</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>disability</term><term>early treatment</term><term>levodopa</term><term>selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000236 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000236 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370
|texte= Experience with selegiline and levodopa in advanced Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |